Amyloidosis Cardiac Stage (Mayo 2012) Calculator

Amyloidosis Cardiac Stage (Mayo 2012): Explanation and Clinical Context The Mayo 2012 staging system is designed for patients with systemic light-chain (AL) amyloidosis and provides prognostic information based on cardiac involvement. It uses three biomarkers: NT-proBNP (>1800 pg/mL), Troponin T (>0.025 ng/mL), and difference in free light chains (dFLC >180 mg/L). Each abnormal biomarker counts as one risk factor.

Stage 1 is defined as no elevated biomarkers, Stage 2 as one elevated biomarker, Stage 3 as two elevated biomarkers, and Stage 3b when all three biomarkers are elevated, indicating the highest risk. This staging system helps clinicians stratify risk, guide treatment decisions, and provide prognostic counseling to patients.